Jim Simons’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.5M | Buy |
1,600,500
+1,337,246
| +508% | +$1.94M | ﹤0.01% | 1773 |
|
|
2025
Q4 | $303K | Sell |
263,254
-29,146
| -10% | -$40K | ﹤0.01% | 2757 |
|
|
2025
Q3 | $395K | Buy |
+292,400
| New | +$332K | ﹤0.01% | 2890 |
|
|
2025
Q1 | – | Sell |
-51,141
| Closed | -$37.8K | – | 3687 |
|
|
2024
Q4 | $37.8K | Buy |
+51,141
| New | +$61.6K | ﹤0.01% | 3422 |
|
|
2024
Q1 | – | Sell |
-412,175
| Closed | -$631K | – | 3919 |
|
|
2023
Q4 | $631K | Buy |
412,175
+139,920
| +51% | +$166K | ﹤0.01% | 2676 |
|
|
2023
Q3 | $297K | Buy |
+272,255
| New | +$478K | ﹤0.01% | 2935 |
|
|
2023
Q2 | – | Sell |
-263,875
| Closed | -$641K | – | 4119 |
|
|
2023
Q1 | $641K | Sell |
263,875
-129,410
| -33% | -$297K | ﹤0.01% | 2746 |
|
|
2022
Q4 | $751K | Sell |
393,285
-88,090
| -18% | -$187K | ﹤0.01% | 2699 |
|
|
2022
Q3 | $1.16M | Buy |
+481,375
| New | +$1.33M | ﹤0.01% | 2404 |
|
|
2022
Q2 | – | Sell |
-88,776
| Closed | -$186K | – | 4436 |
|
|
2022
Q1 | $186K | Buy |
+88,776
| New | +$246K | ﹤0.01% | 3668 |
|
|
2021
Q3 | – | Sell |
-59,775
| Closed | -$274K | – | 3687 |
|
|
2021
Q2 | $274K | Sell |
59,775
-252,704
| -81% | -$1.22M | ﹤0.01% | 3174 |
|
|
2021
Q1 | $1.83M | Sell |
312,479
-682,500
| -69% | -$4.73M | ﹤0.01% | 2285 |
|
|
2020
Q4 | $3.4M | Sell |
994,979
-637,652
| -39% | -$1.22M | ﹤0.01% | 1823 |
|
|
2020
Q3 | $2.35M | Sell |
1,632,631
-247,572
| -13% | -$441K | ﹤0.01% | 2042 |
|
|
2020
Q2 | $3.75M | Buy |
1,880,203
+213,605
| +13% | +$419K | ﹤0.01% | 1819 |
|
|
2020
Q1 | $3.25M | Buy |
1,666,598
+463,420
| +39% | +$1.38M | ﹤0.01% | 1805 |
|
|
2019
Q4 | $4.99M | Buy |
1,203,178
+537,799
| +81% | +$2.07M | ﹤0.01% | 1854 |
|
|
2019
Q3 | $2M | Buy |
665,379
+118,638
| +22% | +$367K | ﹤0.01% | 2285 |
|
|
2019
Q2 | $3.44M | Buy |
546,741
+57,228
| +12% | +$343K | ﹤0.01% | 2041 |
|
|
2019
Q1 | $2.72M | Buy |
489,513
+145,027
| +42% | +$881K | ﹤0.01% | 2152 |
|
|
2018
Q4 | $2.29M | Buy |
344,486
+252,900
| +276% | +$2.05M | ﹤0.01% | 2162 |
|
|
2018
Q3 | $977K | Sell |
91,586
-100,840
| -52% | -$1.16M | ﹤0.01% | 2612 |
|
|
2018
Q2 | $2.31M | Sell |
192,426
-36,660
| -16% | -$375K | ﹤0.01% | 2196 |
|
|
2018
Q1 | $1.96M | Sell |
229,086
-275,800
| -55% | -$2.55M | ﹤0.01% | 2337 |
|
|
2017
Q4 | $4.99M | Buy |
504,886
+216,800
| +75% | +$2.25M | 0.01% | 1806 |
|
|
2017
Q3 | $3.54M | Sell |
288,086
-96,011
| -25% | -$1.42M | ﹤0.01% | 1967 |
|
|
2017
Q2 | $6.32M | Buy |
384,097
+122,592
| +47% | +$1.9M | 0.01% | 1562 |
|
|
2017
Q1 | $3.75M | Buy |
+261,505
| New | +$3.88M | 0.01% | 1870 |
|
|
2015
Q4 | – | Sell |
-11,086
| Closed | -$119K | – | 3361 |
|
|
2015
Q3 | $119K | Sell |
11,086
-159,067
| -93% | -$1.74M | ﹤0.01% | 2984 |
|
|
2015
Q2 | $1.37M | Sell |
170,153
-63,580
| -27% | -$467K | ﹤0.01% | 2291 |
|
|
2015
Q1 | $1.54M | Buy |
233,733
+134,317
| +135% | +$917K | ﹤0.01% | 2071 |
|
|
2014
Q4 | $633K | Buy |
+99,416
| New | +$801K | ﹤0.01% | 2350 |
|
|
2014
Q1 | – | Sell |
-35,192
| Closed | -$443K | – | 2937 |
|
|
2013
Q4 | $443K | Buy |
+35,192
| New | +$560K | ﹤0.01% | 2391 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Jim Simons's LXRX Position: Q1 2026 in Review
Jim Simons increased its Lexicon Pharmaceuticals (LXRX) stake by 508% in Q1 2026, buying an estimated $1.94M and bringing the position to 1,600,500 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1773.
Jim Simons first reported a position in LXRX in Q4 2013 and has held it in 33 quarters since. The position peaked at $6.32M in Q2 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Jim Simons held 1,600,500 shares of Lexicon Pharmaceuticals worth $2.5M as of Q1 2026.
- Jim Simons bought 1,337,246 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $1.94M.
- Lexicon Pharmaceuticals made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1773 holding.
- Jim Simons first reported a position in Lexicon Pharmaceuticals in Q4 2013 and has held it in 33 quarters since.
- Jim Simons's Lexicon Pharmaceuticals position peaked at $6.32M in Q2 2017.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.